Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Research & Development (2021 - 2025)

ARS Pharmaceuticals' Research & Development history spans 5 years, with the latest figure at $3.4 million for Q4 2025.

  • For Q4 2025, Research & Development rose 13.74% year-over-year to $3.4 million; the TTM value through Dec 2025 reached $13.2 million, down 32.68%, while the annual FY2025 figure was $13.2 million, 32.68% down from the prior year.
  • Research & Development for Q4 2025 was $3.4 million at ARS Pharmaceuticals, up from $2.8 million in the prior quarter.
  • Across five years, Research & Development topped out at $17.7 million in Q2 2021 and bottomed at -$25.4 million in Q4 2021.
  • The 5-year median for Research & Development is $4.6 million (2022), against an average of $4.8 million.
  • The largest YoY upside for Research & Development was 118.58% in 2022 against a maximum downside of 75.49% in 2022.
  • A 5-year view of Research & Development shows it stood at -$25.4 million in 2021, then surged by 118.58% to $4.7 million in 2022, then dropped by 27.73% to $3.4 million in 2023, then fell by 11.08% to $3.0 million in 2024, then rose by 13.74% to $3.4 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Research & Development are $3.4 million (Q4 2025), $2.8 million (Q3 2025), and $4.0 million (Q2 2025).